EUVIMEDEUVIMED entdecken
Crossref

Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer

David J Benjamin, Vinay Prasad

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.115058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von David J Benjamin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hoag Family Cancer Institute, Newport Beach, CA, United States. Electronic address: David.Benjamin@hoag.org. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy, Neoplasm Staging. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Arnold Ventures LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Several phase III trials have altered the management of oncogenic driven non-small cell lung cancer (NSCLC) including those harboring EGFR and ALK mutations. However, several of these pivotal trials deviated from standard-of-care practices for either baseline imaging or surveillance imaging. This occurred despite sponsor acknowledgement in a clinical trial protocol that historical trials utilized imaging modalities that potentially under-staged patients. Inadequate baseline imaging for adjuvant trials instead of PET/CT may not identify individuals with metastatic disease, and thereby subject such individuals with metastatic disease to inferior treatment if randomized to the control arm. Similarly, more frequent surveillance imaging than what is considered standard-of-care may identify disease progression earlier than what is expected in real-world clinical practice and therefore embellish the magnitude of benefit between a targeted therapy and the control arm. While targeted therapies have provided clinical benefit for individuals with oncogenic driven NSCLC, physicians and patients must be cognizant that clinical trial deviations from standard-of-care imaging practices may have embellished the magnitude of benefit for several of these therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMolecular Targeted TherapyNeoplasm StagingHumansPositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

ImagingLung cancerTargeted therapies

Autor:innen und Institutionen

  • Hoag Family Cancer Institute, Newport Beach, CA, United States. Electronic address: David.Benjamin@hoag.org.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.

Förderung

  • Arnold Ventures LLC

Zitieren

APA

Benjamin, D. J., & Prasad, V. (2024). Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115058

Vancouver

Benjamin DJ, Prasad V. Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115058

BibTeX
@article{Benjamin2024,
  author = {Benjamin, David J and Prasad, Vinay},
  title = {Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.115058}
}
Kostenlos starten →